StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.
Amid a pullback, health-care companies are preparing for the next phase of the Affordable Care Act.
Although 2015 may be rocky, both Baxter and Baxalta should see significant margin expansion and growth in the long term, says Morningstar's Karen Andersen .
Morningstar CEO of the Year finalist John Martin's smart capital-allocation decisions have helped drive a 100-fold increase in this biopharmaceutical's stock since he took over in 1996.
With an improving pipeline and a new manufacturing technology, Amgen is on the path to stabilizing its moat trend.
Investors should only take risks that the market rewards--and that they can live with.
Hear industry outlooks and best ideas from the 12 Morningstar analysts named by The Wall Street Journal among the "Best on the Street."
Not crushing on IPOs, Facebook's virtual strategy, a setback for Citi, and more.
Cost and scale advantages, as well as greater product focus in the future, are positives for this wide-moat health-care name.